# Clinical Cases: Men's Health in Family Medicine

## Case 1: Benign Prostatic Hyperplasia

### Patient Demographics
- **Age:** 67 years old
- **Sex:** Male
- **Occupation:** Retired postal worker

### Chief Complaint
"I'm getting up to urinate four or five times every night and it's really affecting my sleep."

### History of Present Illness
Mr. Robert Chen is a 67-year-old man presenting with progressive lower urinary tract symptoms over the past 18 months. He reports nocturia four to five times nightly, urinary frequency during the day (voiding every 2-3 hours), hesitancy taking 30-60 seconds to initiate urination, weak urinary stream, and a sensation of incomplete bladder emptying. He denies dysuria, hematuria, or urinary incontinence. He has not had any episodes of acute urinary retention. The symptoms have significantly impacted his quality of life, causing daytime fatigue and difficulty concentrating due to disrupted sleep.

### Past Medical History
- Type 2 diabetes mellitus (well-controlled, HbA1c 6.8%)
- Hypertension on lisinopril
- Hyperlipidemia on atorvastatin

### Medications
- Lisinopril 20 mg daily
- Atorvastatin 40 mg daily
- Metformin 1000 mg twice daily

### Family History
- Father: BPH, prostatectomy at age 72
- No family history of prostate cancer

### Social History
- Non-smoker
- Occasional alcohol (1-2 beers on weekends)
- Married, two adult children
- Moderate caffeine intake (2-3 cups coffee daily)

### Physical Examination
- **Vital Signs:** BP 132/78 mmHg, HR 72, BMI 28
- **General:** Well-appearing, no acute distress
- **Abdomen:** Soft, non-tender, no suprapubic fullness or masses
- **Digital Rectal Examination:**
  - Prostate: Symmetrically enlarged, approximately 50 grams
  - Smooth, rubbery consistency
  - No nodules or asymmetry
  - Non-tender
  - Median sulcus palpable

### Clinical Image
![Benign Prostatic Hyperplasia Diagram](case_01_image.jpg)

*Image: Anatomical diagram demonstrating benign prostatic hyperplasia with enlargement of the transition zone compressing the prostatic urethra, leading to bladder outlet obstruction.*

**Image Source:** Wikimedia Commons
**Attribution:** BruceBlaus, CC BY-SA 4.0
**URL:** https://commons.wikimedia.org/wiki/File:Benign_Prostatic_Hyperplasia.png

### Laboratory and Diagnostic Studies
- **Urinalysis:** Normal, no infection
- **PSA:** 3.2 ng/mL (within normal limits for age)
- **Serum creatinine:** 1.1 mg/dL (normal)
- **Post-void residual (bladder scan):** 120 mL (mildly elevated)
- **International Prostate Symptom Score (IPSS):** 19 (moderate symptoms)
- **IPSS Bother Score:** 5/6 (significantly bothered)

### Assessment and Diagnosis
1. **Benign prostatic hyperplasia** with moderate lower urinary tract symptoms (IPSS 19)
2. **Nocturia** - significantly impacting quality of life
3. Type 2 diabetes mellitus - well controlled
4. Hypertension - controlled

### Management Plan

**Lifestyle Modifications:**
- Reduce evening fluid intake, especially 2-3 hours before bedtime
- Reduce caffeine consumption
- Avoid alcohol close to bedtime
- Practice double voiding (void, wait, void again)
- Avoid over-the-counter decongestants containing pseudoephedrine

**Pharmacologic Treatment:**
- **Tamsulosin 0.4 mg daily** (alpha-1 adrenergic blocker)
  - Start at bedtime to minimize orthostatic hypotension
  - Expect symptom improvement within 1-2 weeks
  - Counseled about potential side effects: dizziness, retrograde ejaculation, nasal congestion
  - Warned about intraoperative floppy iris syndrome if cataract surgery needed

**Patient Education:**
- Explained the nature of BPH and that it is not prostate cancer
- Discussed the natural history: variable progression
- Reviewed when to seek urgent care (complete inability to urinate)

### Follow-Up
- Return in 4-6 weeks to assess symptom response
- Repeat IPSS at follow-up to quantify improvement
- If inadequate response, consider adding a 5-alpha reductase inhibitor (finasteride) given prostate size >30-40g
- Annual PSA monitoring with shared decision-making discussion

### Teaching Points
1. **IPSS scoring guides treatment:** Mild (0-7) = watchful waiting; Moderate (8-19) = medical therapy; Severe (20-35) = consider surgery referral

2. **Alpha-blockers provide rapid relief** (days to weeks) through smooth muscle relaxation in the prostate and bladder neck

3. **5-alpha reductase inhibitors (finasteride, dutasteride)** take 6-12 months for full effect but reduce prostate size and progression risk; remember they reduce PSA by approximately 50%

4. **Digital rectal examination findings:** Smooth, rubbery, symmetric enlargement suggests BPH; nodules, asymmetry, or firmness require urology referral and further evaluation for malignancy

5. **Tamsulosin and cataract surgery:** Patients should inform ophthalmologists about alpha-blocker use due to intraoperative floppy iris syndrome risk

---

## Case 2: Erectile Dysfunction with Cardiovascular Risk

### Patient Demographics
- **Age:** 54 years old
- **Sex:** Male
- **Occupation:** Construction supervisor

### Chief Complaint
"I've been having trouble maintaining an erection. It's been going on for about six months now."

### History of Present Illness
Mr. James Walker is a 54-year-old man presenting with erectile dysfunction that has gradually worsened over the past 6-8 months. He describes difficulty achieving and maintaining erections sufficient for intercourse. He can still achieve partial erections but they are not firm enough and do not last. Morning erections have also decreased in frequency and quality. He denies loss of libido, premature ejaculation, or relationship problems with his wife. He has not tried any medications for this condition. The problem has caused significant distress and he reports avoiding intimacy due to embarrassment.

### Past Medical History
- Hypertension (diagnosed 3 years ago)
- Prediabetes (HbA1c 5.9%)
- No prior cardiac events
- No prior surgeries

### Medications
- Hydrochlorothiazide 25 mg daily

### Family History
- Father: Myocardial infarction at age 58
- Mother: Type 2 diabetes

### Social History
- Smokes 1 pack per day for 30 years (30 pack-years)
- Alcohol: 3-4 beers most evenings
- Married for 28 years
- Sedentary lifestyle, no regular exercise
- High-stress job

### Physical Examination
- **Vital Signs:** BP 148/92 mmHg, HR 78, BMI 31
- **General:** Overweight male, appears older than stated age
- **Cardiovascular:** Regular rhythm, no murmurs, peripheral pulses slightly diminished in feet
- **Genitourinary:** Normal external genitalia, testes normal size and consistency, no penile plaques
- **Secondary sex characteristics:** Normal male hair pattern, no gynecomastia

### Clinical Image
![Atherosclerosis Comparison](case_02_image.jpg)

*Image: Cross-sectional comparison of normal artery versus atherosclerotic artery demonstrating plaque buildup that narrows the vessel lumen. The penile arteries are smaller than coronary arteries and may show symptoms of vascular insufficiency earlier.*

**Image Source:** Wikimedia Commons
**Attribution:** National Heart Lung and Blood Institute, Public Domain
**URL:** https://commons.wikimedia.org/wiki/File:Atherosclerosis_diagram.png

### Laboratory Studies
- **Fasting glucose:** 118 mg/dL (impaired)
- **HbA1c:** 6.0%
- **Lipid panel:**
  - Total cholesterol: 248 mg/dL (high)
  - LDL: 168 mg/dL (high)
  - HDL: 38 mg/dL (low)
  - Triglycerides: 210 mg/dL (high)
- **Total testosterone (morning):** 385 ng/dL (low-normal)
- **TSH:** 2.1 mIU/L (normal)
- **Serum creatinine:** 1.0 mg/dL

### Assessment and Diagnosis
1. **Erectile dysfunction** - likely vasculogenic etiology given cardiovascular risk profile
2. **Cardiovascular risk factors** - erectile dysfunction as potential early marker of systemic atherosclerosis
3. **Uncontrolled hypertension** - current BP above goal
4. **Dyslipidemia** - untreated, high LDL, low HDL
5. **Prediabetes** - progressing toward diabetes
6. **Tobacco use disorder**
7. **Alcohol use** - possibly excessive

### Management Plan

**Cardiovascular Risk Assessment and Management (Primary Focus):**
- Calculated 10-year ASCVD risk: 18% (high)
- Initiate **atorvastatin 40 mg daily** for primary prevention
- Optimize blood pressure control:
  - Continue hydrochlorothiazide
  - Add **lisinopril 10 mg daily** (ACE inhibitor preferable given metabolic syndrome)
- Consider switching thiazide if ED persists (thiazides can contribute to ED)

**Erectile Dysfunction Treatment:**
- After confirming no contraindications (not on nitrates):
- **Sildenafil 50 mg** as needed, 30-60 minutes before sexual activity
- May increase to 100 mg or decrease to 25 mg based on response and tolerability
- Maximum once daily
- Counseled on side effects: headache, flushing, nasal congestion, visual changes

**Critical Counseling on Nitrate Contraindication:**
- Absolute contraindication: Do NOT use nitroglycerin or any nitrate within 24 hours of sildenafil (48 hours for tadalafil)
- Combination can cause severe, potentially fatal hypotension
- If chest pain occurs, seek emergency care but inform providers about sildenafil use

**Lifestyle Modifications (Most Important Long-Term):**
- **Smoking cessation:** Discussed as single most important intervention; offered nicotine replacement and referral to cessation program
- **Weight loss:** Target 5-10% weight reduction
- **Exercise:** Start with 30 minutes moderate activity most days
- **Alcohol reduction:** Limit to 1-2 drinks per day maximum
- **Dietary counseling:** Mediterranean-style diet

### Follow-Up
- Blood pressure recheck in 2 weeks
- Repeat lipids in 6-8 weeks
- Return visit in 4-6 weeks to assess ED treatment response
- If ED improves with risk factor modification, may eventually reduce reliance on PDE5 inhibitors
- Consider cardiology referral for stress testing given multiple risk factors

### Teaching Points
1. **Erectile dysfunction is a cardiovascular warning sign:** The penile arteries (1-2 mm) are smaller than coronary arteries (3-4 mm) and may manifest atherosclerosis earlier - ED may precede coronary events by 2-5 years

2. **Comprehensive cardiovascular risk assessment is mandatory** when evaluating ED, including lipids, glucose, blood pressure, and lifestyle factors

3. **PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are first-line ED therapy** but are absolutely contraindicated with nitrate use

4. **Lifestyle modifications (smoking cessation, weight loss, exercise) address the root cause** and may improve ED independent of pharmacotherapy

5. **Thiazide diuretics and some beta-blockers can contribute to ED** - consider medication review and alternatives when appropriate

---

## Case 3: Prostate Cancer Screening Discussion

### Patient Demographics
- **Age:** 58 years old
- **Sex:** Male
- **Race:** African American
- **Occupation:** High school principal

### Chief Complaint
"My brother was just diagnosed with prostate cancer. Should I get tested?"

### History of Present Illness
Mr. Marcus Johnson is a 58-year-old African American man presenting for discussion of prostate cancer screening. His 62-year-old brother was recently diagnosed with localized prostate cancer after an elevated PSA was found during a routine physical. This has prompted significant concern, and he wants to know if he should be tested. He denies any urinary symptoms, bone pain, or weight loss. He has never had a PSA test.

### Past Medical History
- Hypertension, well-controlled
- No prior cancers or surgeries

### Family History
- Brother: Prostate cancer, age 62, currently undergoing treatment
- Father: Died at 78, cause unknown (no cancer history)
- No other known family history of prostate or other cancers

### Social History
- Non-smoker
- Occasional alcohol
- Married, three adult children
- Exercises regularly (walks 30 minutes daily)

### Physical Examination
- **Vital Signs:** BP 128/76 mmHg, HR 68, BMI 27
- **General:** Healthy-appearing, no acute distress
- **Digital Rectal Examination:**
  - Prostate: Normal size, smooth, symmetric
  - No nodules, no tenderness
  - Normal sphincter tone

### Clinical Image
![Prostate Cancer Screening Discussion](case_03_image.jpg)

*Image: Illustration depicting the shared decision-making process for prostate cancer screening, showing a balance scale weighing the potential benefits (early detection, possible mortality reduction) against harms (false positives, overdiagnosis, treatment side effects).*

**Image Source:** Wikimedia Commons
**Attribution:** National Cancer Institute, Public Domain
**URL:** https://commons.wikimedia.org/wiki/File:Prostate_cancer_screening_decision.jpg

### Shared Decision-Making Discussion

**Risk Factors Identified:**
- African American race: 60% higher incidence and 2-3 times higher mortality than white men
- First-degree relative with prostate cancer: approximately 2x risk
- Combined risk factors place patient in HIGH-RISK category

**Benefits of PSA Screening Discussed:**
- May detect prostate cancer earlier when potentially curable
- Possible modest reduction in prostate cancer mortality (1-2 deaths prevented per 1,000 men screened over 10-15 years)
- Peace of mind with negative result
- For high-risk men, potential benefit may be greater

**Harms of PSA Screening Discussed:**
- High false-positive rate leading to unnecessary biopsies
- Biopsy complications: pain, bleeding, infection
- Overdiagnosis of cancers that would never cause harm (estimated 20-50% of screen-detected cancers)
- Overtreatment with associated side effects:
  - Erectile dysfunction (30-60% after treatment)
  - Urinary incontinence (10-20% after treatment)
  - Bowel problems with radiation
- Anxiety from positive results

**USPSTF Recommendation:**
- For men 55-69: Grade C (individualized decision through shared decision-making)
- For this patient: Given high-risk status (African American + family history), professional organizations recommend initiating discussion at age 40-45 and screening may be more beneficial

### Patient's Decision and Values
- Patient expressed high value on early detection given brother's diagnosis
- Concerned about potential cancer but also about treatment side effects
- Understood that positive PSA does not equal cancer diagnosis
- After thorough discussion, patient chose to proceed with PSA testing

### Assessment and Plan
1. **Prostate cancer risk counseling** completed with shared decision-making
2. Patient is **high-risk** (African American + first-degree relative with prostate cancer)
3. Patient **elects PSA screening** after informed discussion

**Laboratory Ordered:**
- PSA level

**Follow-Up Plan:**
- Results will be discussed at follow-up visit or by phone
- If PSA elevated (>4 ng/mL or age-specific threshold):
  - Repeat PSA to confirm
  - Calculate free PSA ratio
  - Urology referral for consideration of multiparametric MRI and possible biopsy
- If PSA normal:
  - Annual screening per patient preference
  - Continue shared decision-making at each visit

### Documentation
- Documented detailed discussion of risks, benefits, and alternatives
- Patient understood the information and made informed decision
- Written consent for PSA testing obtained

### Teaching Points
1. **Shared decision-making is mandatory** for prostate cancer screening - the clinician must discuss benefits AND harms

2. **African American men and those with family history are at significantly elevated risk** and may benefit more from screening; professional organizations recommend earlier discussion (age 40-45)

3. **PSA is not a cancer test** - it is a marker of prostate pathology (also elevated in BPH, prostatitis, instrumentation)

4. **The harms of screening include overdiagnosis and overtreatment** - many detected cancers would never cause clinical harm during the patient's lifetime

5. **Active surveillance is now the preferred management** for low-risk prostate cancer, avoiding immediate treatment side effects while monitoring for progression

6. **Document the shared decision-making discussion** thoroughly in the medical record

---

## Key Teaching Points Summary

### Men's Health Disparities
- Men have 5 years shorter life expectancy than women
- Men are less likely to seek preventive care
- Suicide rate in men is 4 times higher than women despite lower depression diagnosis rates

### Prostate Conditions
- BPH: Use IPSS scoring to guide treatment; alpha-blockers for rapid relief; 5-ARIs for larger prostates
- PSA screening requires shared decision-making; high-risk groups benefit from earlier discussion
- Digital rectal examination cannot reliably distinguish BPH from cancer

### Erectile Dysfunction
- Consider ED as a cardiovascular warning sign - evaluate and address risk factors
- PDE5 inhibitors are absolutely contraindicated with nitrates
- Lifestyle modifications (smoking cessation, weight loss, exercise) address root cause

### Clinical Pearls
- Tamsulosin: warn patients about intraoperative floppy iris syndrome before cataract surgery
- 5-alpha reductase inhibitors reduce PSA by ~50% - must adjust when interpreting PSA results
- Thiazide diuretics and some beta-blockers can contribute to erectile dysfunction